TY - JOUR
AU1 - Maguire, Maureen G.
AU2 - Fine, Stuart L.
AU3 - Folk, James C.
AU4 - Bressler, Neil M.
AU5 - Javornik, Noreen B.
AU6 - Alexander, Judith
AU7 - Chandra, Suresh
AU8 - Schachat, Andrew P.
AB - This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables. Abstract In reply We thank Dr Tiedeman for his careful reading of our article and his thoughtful comments. As we emphasized in our discussion, advising whether a particular patient should be treated with laser photocoagulation involves consideration of both short- and long-term effects of the treatment and characteristics of the patient such as the condition of the fellow eye. We and Dr Tiedeman are in agreement that the reason that group B patients are good candidates for immediate treatment is the reduced risk for severe loss of vision that begins at 12 months after treatment and endures for at least 3 additional years. This sustained period of lower risk for loss of vision outweighs, in our opinion, the period of increased risk immediately following treatment. In reply Members of the Macular Photocoagulation Study Group are listed in the April issue of the Archives on page 482.
TI - Treatment of Subfoveal Choroidal Neovascularization-Reply
JF - Archives of Ophthalmology
DO - 10.1001/archopht.1995.01100020015010
DA - 1995-02-01
UR - https://www.deepdyve.com/lp/american-medical-association/treatment-of-subfoveal-choroidal-neovascularization-reply-mUsV0baTMs
SP - 138
EP - 138
VL - 113
IS - 2
DP - DeepDyve
ER -